Pfizer Rating Reiterated by TheStreet (PFE)
Pfizer (NYSE:PFE)‘s stock had its “buy” rating reaffirmed by stock analysts at TheStreet in a report issued on Monday, AnalystRatings.Net reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Shares of Pfizer (NYSE:PFE) traded down 0.49% during mid-day trading on Monday, hitting $30.54. 23,992,314 shares of the company’s stock traded hands. Pfizer has a 52-week low of $26.34 and a 52-week high of $32.50. The stock’s 50-day moving average is $30.8 and its 200-day moving average is $29.72. The company has a market cap of $197.9 billion and a P/E ratio of 8.47. Pfizer also was the recipient of unusually large options trading on Monday. Traders bought 29,371 call options on the company. This represents an increase of approximately 134% compared to the typical volume of 12,551 call options.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.56 by $0.02. The company had revenue of $12.64 billion for the quarter, compared to the consensus estimate of $12.69 billion. During the same quarter last year, the company posted $0.53 earnings per share. Pfizer’s revenue was down 2.4% compared to the same quarter last year. Analysts expect that Pfizer will post $2.18 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, March 4th. Shareholders of record on Friday, February 7th will be given a dividend of 0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date of this dividend is Wednesday, February 5th. This is a positive change from Pfizer’s previous quarterly dividend of $0.24.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cowen and Company downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating in a research note to investors on Friday. They now have a $34.00 price target on the stock. Separately, analysts at UBS AG downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note to investors on Thursday. Finally, analysts at Jefferies Group raised their price target on shares of Pfizer from $31.00 to $33.00 in a research note to investors on Thursday. They now have a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $31.78.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.